Hims & Hers Health, Inc. (HIMS) is trading at $25.37, down 5.3% with a composite score of -3/100, indicating a disconnect between the recent bullish news sentiment and the stock's price action, particularly with a 30.2% options-implied expected move. The FDA's scheduled peptide review and a potential policy shift have driven a bullish narrative, but with a forward P/E of 17.9 and a rich IV/RV ratio of 3.75x, the market is pricing in significant uncertainty. The key question is whether the company's 28% revenue growth and 5% margin can justify the current valuation and drive the stock above the $24 target, or if short interest of 38.7% will continue to weigh on the stock.
Composite
-3
/ 100
1M
-2.8%
3M
-22.4%
6M
-55.0%
1Y
-14.2%
Trend
UP
Sharpe
0.15
Fundamentals
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Market Cap
$6B
Fwd P/E
17.9
Trail P/E
49.8
Beta
2.31
Short Interest
38.7%
Analyst Target
$24
Margin
5%
Rev Growth
28%
EPS Growth
-17%
ROE
25%
D/E
207%
From 52w High
-63.9%
From 52w Low
+84.8%
Consensus
Hold
Research Digest
Hims & Hers stock rose after the FDA scheduled a review of 7 popular peptides, potentially expanding access and opening a new market for the company. The review could allow compounding pharmacies to produce these peptides, which are part of Hims' product offerings. However, the path to expanded access remains uncertain, posing a risk to the thesis.